Neurocrine Biosciences Inc (NBIX) Stock Analysis
Verdict: BUY
Core INGREZZA growth and pipeline diversification drive a 120% earnings surge, yet heavy insider selling creates a tactical ceiling.
Investment score: 74/100
Analysis as of
Is Neurocrine Biosciences Inc stock worth reviewing? The TradeMates thesis
Neurocrine is evolving from a single-drug story into a diversified powerhouse with elite margins and accelerating profitability.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 95/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 90/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 80/100 (weight 15%)
Neurocrine Biosciences Inc opportunities and risks
What speaks for NBIX
- Explosive Earnings Growth Pipeline
What speaks against NBIX
- Aggressive Insider Divestment
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NBIX | 23.9x | 5.0x | 18.1x | 98.0% | 20.9% | 5.1% |
| INCY | 14.7x | 4.2x | 9.9x | 92.6% | 27.7% | 7.9% |
| MRNA | n/a | 10.1x | n/a | -12.6% | -141.4% | -5.4% |
| UTHR | 17.7x | 6.9x | 12.2x | 86.6% | 40.6% | 4.6% |
| INSM | n/a | 25.9x | n/a | 81.6% | -144.4% | -4.5% |
| BBIO | n/a | 26.9x | n/a | 93.8% | -125.2% | -2.9% |
| Peer median | n/a | 10.1x | n/a | 86.6% | -125.2% | -2.9% |
Frequently asked questions about Neurocrine Biosciences Inc (NBIX)
Is NBIX stock a good investment?
The TradeMates model rates Neurocrine Biosciences Inc as BUY with an investment score of 74/100. Neurocrine is evolving from a single-drug story into a diversified powerhouse with elite margins and accelerating profitability. This is algorithmic model output, not personal investment advice.
Is NBIX stock a buy?
The TradeMates model verdict for NBIX is BUY with an investment score of 74/100. Treat this as a model signal to review, not a personal buy recommendation.